Cargando…
Drug discovery in leishmaniasis using protein lipidation as a target
The leishmaniases are infectious diseases caused by a number of species of obligate intracellular protozoa of the genus Leishmania with disease manifesting as cutaneous, mucocutaneous and visceral forms. Despite being endemic in more than 80 countries and its being the cause of high morbidity and mo...
Autores principales: | Brannigan, James A., Wilkinson, Anthony J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724199/ https://www.ncbi.nlm.nih.gov/pubmed/35035594 http://dx.doi.org/10.1007/s12551-021-00855-0 |
Ejemplares similares
-
N-Myristoyltransferase from Leishmania donovani: Structural and Functional Characterisation of a Potential Drug Target for Visceral Leishmaniasis
por: Brannigan, James A., et al.
Publicado: (2010) -
Visceral leishmaniasis: Experimental models for drug discovery
por: Gupta, Suman, et al.
Publicado: (2011) -
Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites
por: Olaleye, Tayo O., et al.
Publicado: (2014) -
Chemoinformatics Strategies for Leishmaniasis Drug Discovery
por: Ferreira, Leonardo L. G., et al.
Publicado: (2018) -
Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis
por: Alcântara, Laura M., et al.
Publicado: (2018)